Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26FM7J9
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $31,426
Award facts
- Contract value 100% obligated
- $31,426.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $31,426.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The product will be performed from the contractor's Conshohocken, Pennsylvania facility, which serves as the company's corporate headquarters and primary distribution hub for federal medical procurement.
Repatha (evolocumab) is a PCSK9 inhibitor indicated for cardiovascular disease management, and this delivery order supports the Defense Health Agency's pharmaceutical supply chain for military healthcare systems. AmerisourceBergen's SPE2DX contract serves as a comprehensive vehicle enabling supply of specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains to support military personnel and veterans worldwide. The Pharmaceutical Prime Vendor Global Program Generation V contracts, under which this award was made, represent DLA's strategic approach to establishing multiple regional pharmaceutical supply agreements with qualified vendors to ensure robust, flexible support for federal healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FM7J9?
SPE2DR26FM7J9 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26FM7J9 worth?
The government has obligated $31,426 on SPE2DR26FM7J9.
Is contract SPE2DR26FM7J9 an order under another contract?
Yes. SPE2DR26FM7J9 is a delivery order under SPE2DR25D2211, an indefinite delivery contract.
Was contract SPE2DR26FM7J9 competed?
The extent of competition for SPE2DR26FM7J9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award